Vir Biotechnology https://www.biospace.com/employer/1828518/vir Vir Biotechnology en-US Wed, 25 Mar 2020 13:20:06 GMT Vir Biotech IDs Two Antibodies That Could Be Effective in Preventing and Treating COVID-19 https://www.biospace.com/vir-biotechnology-ids-2-monoclonal-antibodies-against-the-covid-19-coronavirus Mark Terry The lead antibody’s ability to neutralize the SARS-CoV-2 live virus has been confirmed in two different laboratories. Wed, 25 Mar 2020 13:20:06 GMT https://www.biospace.com/vir-biotechnology-ids-2-monoclonal-antibodies-against-the-covid-19-coronavirus GSK Strikes Deals with Vir Biotechnology and China’s Innovax Biotech Against COVID-19 https://www.biospace.com/gsk-strikes-vaccine-deal-with-china-s-innovax-against-covid-19 Alex Keown Following close on the heels of its vaccine development agreement with China’s Xiamen Innovax Biotech, GlaxoSmithKline forged a research and development deal with Vir Biotechnology to develop treatments for COVID-19. Mon, 06 Apr 2020 13:24:48 GMT https://www.biospace.com/gsk-strikes-vaccine-deal-with-china-s-innovax-against-covid-19 Vir Shares Findings from Phase 1/2 Trial for VIR-2218 in Hepatitis B Virus https://www.biospace.com/phase-1-2-trial-of-vir-biotechnology-s-vir-2218-shows-promising-dose-dependent-and-durable-reductions-of-hepatitis-b-surface-antigen Michelle Brugioni Data from the ongoing Phase II trial, as well as results from the Phase I trial of VR-2218, was released during a live webcast presentation on Wednesday. Thu, 16 Apr 2020 20:03:43 GMT https://www.biospace.com/phase-1-2-trial-of-vir-biotechnology-s-vir-2218-shows-promising-dose-dependent-and-durable-reductions-of-hepatitis-b-surface-antigen Vir Bio and GSK Join the Race for a COVID-19 Monoclonal Antibody Therapy https://www.biospace.com/vir-bio-and-gsk-dose-first-patient-with-covid-19-in-monoclonal-antibody-trial Mark Terry Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19. Mon, 31 Aug 2020 14:14:44 GMT https://www.biospace.com/vir-bio-and-gsk-dose-first-patient-with-covid-19-in-monoclonal-antibody-trial Vir Bio’s COVID-19 Antibody Therapy Could be Great, But Will It Be Too Late? https://www.biospace.com/vir-bio-s-covid-19-antibody-therapy-may-be-great-but-will-it-be-too-late Mark Terry San Francisco-based Vir Biotechnology and its chief executive officer, George Scangos, believe it has a terrific antibody therapy against SARS-CoV-2, the virus that causes COVID-19. But is it too late to the game? Wed, 11 Nov 2020 13:25:39 GMT https://www.biospace.com/vir-bio-s-covid-19-antibody-therapy-may-be-great-but-will-it-be-too-late Vir and GSK Dose First Patient in COVID-19 Monoclonal Antibody Study and Other Pandemic Updates https://www.biospace.com/monoclonal-antibody-moves-into-nih-sponsored-phase-iii-covid-19-study-and-other-pandemic-news Alex Keown Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study assessing the monoclonal antibody VIR-7831 as a potential treatment of hospitalized adults diagnosed with COVID-19. Fri, 18 Dec 2020 15:20:55 GMT https://www.biospace.com/monoclonal-antibody-moves-into-nih-sponsored-phase-iii-covid-19-study-and-other-pandemic-news Vir and GSK Team Up with Eli Lilly for Double Monoclonal Antibody Study https://www.biospace.com/vir-biotechnology-pairs-monoclonal-antibody-with-eli-lilly-s-bamlanivimab Alex Keown Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate its investigational monoclonal antibody, VIR-7831, in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate COVID-19. Wed, 27 Jan 2021 13:30:06 GMT https://www.biospace.com/vir-biotechnology-pairs-monoclonal-antibody-with-eli-lilly-s-bamlanivimab GSK and Vir Expand Antiviral Pact in $645 Million-Plus Deal https://www.biospace.com/vir-and-gsk-expand-existing-collaboration-on-coronaviruses-to-include-flu-and-others Mark Terry In 2020, Vir and GlaxoSmithKline partnered to develop strategies against COVID-19. The two companies have expanded that collaboration to include work into new treatments for influenza and other respiratory viruses. Wed, 17 Feb 2021 13:37:24 GMT https://www.biospace.com/vir-and-gsk-expand-existing-collaboration-on-coronaviruses-to-include-flu-and-others Vir, GSK Halt Trial Enrollment for COVID-19 Antibody Candidate Following Dull Results https://www.biospace.com/vir-gsk-halt-trial-enrollment-for-covid-19-antibody-candidate-following-discouraging-results Kristiane Polido The study of VIR-7831, which is a dual-action SARS-CoV-2 monoclonal antibody, was recommended to be closed to enrollment by an independent data monitoring board, stating that "there were no reported safety signals, sensitivity analyses of the available data raised concerns about the magnitude of potential benefit." Wed, 03 Mar 2021 17:50:13 GMT https://www.biospace.com/vir-gsk-halt-trial-enrollment-for-covid-19-antibody-candidate-following-discouraging-results COVID-19 Wins and Losses: Genentech’s Actemra Flunks Trial; Vir & GSK’s Antibody Dazzles https://www.biospace.com/covid-19-good-news-and-bad-news-genentech-s-actemra-flunks-trial-vir-and-gsk-s-antibody-dazzles Mark Terry Genentech reported its rheumatoid arthritis drug Actemra failed to hit its primary endpoint in a COVID-19 trial, while Vir and GlaxoSmithKline’s antibody against COVID-19 demonstrated 85% efficacy. Thu, 11 Mar 2021 17:17:33 GMT https://www.biospace.com/covid-19-good-news-and-bad-news-genentech-s-actemra-flunks-trial-vir-and-gsk-s-antibody-dazzles